Does the media favor LMAT or GKOS?

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 3 articles in the media. LeMaitre Vascular's average media sentiment score of 1.04 beat Glaukos' score of 0.16 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LMAT or BLCO?

In the previous week, Bausch + Lomb had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Bausch + Lomb and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Bausch + Lomb's score of 0.60 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate STVN or LMAT?

LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 22.87%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 LeMaitre Vascular 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media prefer STVN or LMAT?

In the previous week, Stevanato Group had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Stevanato Group and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Stevanato Group's score of 0.80 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, LMAT or LQDA?

LeMaitre Vascular has higher revenue and earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.39 $57.73M $2.71 33.82 Liquidia $158.32M 31.19 -$68.92M $0.14 396.64

Does the media favor LMAT or LQDA?

In the previous week, Liquidia had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 8 mentions for Liquidia and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Liquidia's score of 0.75 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LIVN or LMAT?

In the previous week, LeMaitre Vascular had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for LeMaitre Vascular and 2 mentions for LivaNova. LeMaitre Vascular's average media sentiment score of 1.04 beat LivaNova's score of 0.58 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LeMaitre Vascular (LMAT) Competitors

$91.64 +0.02 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$92.78 +1.14 (+1.24%)

As of 06:43 PM Eastern

Compare

LMAT vs. GKOS, BLCO, STVN, LQDA, and LIVN

Should you buy LeMaitre Vascular stock or one of its competitors? MarketBeat compares LeMaitre Vascular with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LeMaitre Vascular include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does LeMaitre Vascular compare to Glaukos?

LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

LeMaitre Vascular currently has a consensus price target of $112.60, suggesting a potential upside of 22.87%. Glaukos has a consensus price target of $146.17, suggesting a potential upside of 28.99%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

LeMaitre Vascular has a net margin of 24.35% compared to Glaukos' net margin of -34.34%. LeMaitre Vascular's return on equity of 15.36% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Glaukos	-34.34%	-6.92%	-5.25%

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82
Glaukos	$507.44M	13.11	-$187.69M	-$3.28	N/A

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 3 articles in the media. LeMaitre Vascular's average media sentiment score of 1.04 beat Glaukos' score of 0.16 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

LeMaitre Vascular beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Bausch + Lomb?

LeMaitre Vascular (NASDAQ:LMAT) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LeMaitre Vascular currently has a consensus target price of $112.60, indicating a potential upside of 22.87%. Bausch + Lomb has a consensus target price of $17.92, indicating a potential upside of 20.30%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, equities research analysts clearly believe LeMaitre Vascular is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Bausch + Lomb had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Bausch + Lomb and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Bausch + Lomb's score of 0.60 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

LeMaitre Vascular has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82
Bausch + Lomb	$5.10B	1.04	-$360M	-$0.62	N/A

LeMaitre Vascular has a net margin of 24.35% compared to Bausch + Lomb's net margin of -4.21%. LeMaitre Vascular's return on equity of 15.36% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Bausch + Lomb	-4.21%	3.60%	1.69%

Summary

LeMaitre Vascular beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 22.87%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

LeMaitre Vascular has a net margin of 24.35% compared to Stevanato Group's net margin of 11.76%. LeMaitre Vascular's return on equity of 15.36% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, Stevanato Group had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Stevanato Group and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Stevanato Group's score of 0.80 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than LeMaitre Vascular. Stevanato Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.20	€158.21M	€0.59	31.53
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82

84.6% of LeMaitre Vascular shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LeMaitre Vascular beats Stevanato Group on 12 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Liquidia?

LeMaitre Vascular (NASDAQ:LMAT) and Liquidia (NASDAQ:LQDA) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LeMaitre Vascular has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

LeMaitre Vascular has a net margin of 24.35% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Liquidia	7.74%	46.82%	7.06%

LeMaitre Vascular has higher revenue and earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82
Liquidia	$158.32M	31.19	-$68.92M	$0.14	396.64

In the previous week, Liquidia had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 8 mentions for Liquidia and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.04 beat Liquidia's score of 0.75 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular presently has a consensus target price of $112.60, indicating a potential upside of 22.87%. Liquidia has a consensus target price of $50.88, indicating a potential downside of 8.38%. Given LeMaitre Vascular's higher possible upside, equities research analysts plainly believe LeMaitre Vascular is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Summary

Liquidia beats LeMaitre Vascular on 9 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to LivaNova?

LivaNova (NASDAQ:LIVN) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

LeMaitre Vascular has lower revenue, but higher earnings than LivaNova. LeMaitre Vascular is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.82	-$242.47M	$1.95	36.56
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82

LeMaitre Vascular has a net margin of 24.35% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
LeMaitre Vascular	24.35%	15.36%	9.78%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LivaNova currently has a consensus target price of $79.38, indicating a potential upside of 11.35%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 22.87%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, LeMaitre Vascular had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for LeMaitre Vascular and 2 mentions for LivaNova. LeMaitre Vascular's average media sentiment score of 1.04 beat LivaNova's score of 0.58 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

LeMaitre Vascular beats LivaNova on 11 of the 17 factors compared between the two stocks.

Get LeMaitre Vascular News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMAT vs. The Competition

Export

Metric	LeMaitre Vascular	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.09B	$8.16B	$6.47B	$12.54B
Dividend Yield	1.09%	2.61%	2.69%	5.22%
P/E Ratio	33.82	15.39	22.39	24.18
Price / Sales	8.39	7.06	520.79	112.26
Price / Cash	31.57	17.10	41.34	57.13
Price / Book	5.28	3.53	9.84	6.72
Net Income	$57.73M	$224.05M	$3.57B	$337.19M
7 Day Performance	-4.26%	-1.09%	-1.16%	0.48%
1 Month Performance	-18.21%	0.34%	3.85%	5.07%
1 Year Performance	10.60%	-0.29%	27.40%	34.25%

LeMaitre Vascular Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMAT LeMaitre Vascular	4.8589 of 5 stars	$91.64 +0.0%	$112.60 +22.9%	+14.0%	$2.09B	$249.60M	33.82	490	Positive News Analyst Forecast
GKOS Glaukos	2.8705 of 5 stars	$116.03 -3.5%	$146.17 +26.0%	+17.1%	$6.81B	$507.44M	N/A	1,094
BLCO Bausch + Lomb	4.7379 of 5 stars	$15.94 +0.1%	$18.08 +13.4%	+30.7%	$5.68B	$5.10B	N/A	13,000	Analyst Forecast
STVN Stevanato Group	2.6114 of 5 stars	€18.12 +0.6%	N/A	-14.0%	€5.49B	€1.34B	30.72	6,010	News Coverage Analyst Upgrade
LQDA Liquidia	2.5053 of 5 stars	$61.37 +0.6%	$49.33 -19.6%	+226.7%	$5.46B	$158.32M	438.39	50	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMAT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, BLCO, STVN, LQDA, and LIVN

How does LeMaitre Vascular compare to Glaukos?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Summary

How does LeMaitre Vascular compare to Liquidia?

Summary

How does LeMaitre Vascular compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, BLCO, STVN, LQDA, and LIVN

How does LeMaitre Vascular compare to Glaukos?

Do analysts prefer LMAT or GKOS?

Is LMAT or GKOS more profitable?

Which has higher valuation and earnings, LMAT or GKOS?

Does the media favor LMAT or GKOS?

Which has more volatility and risk, LMAT or GKOS?

Do insiders and institutionals hold more shares of LMAT or GKOS?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Do insiders and institutionals believe in LMAT or BLCO?

Do analysts prefer LMAT or BLCO?

Does the media refer more to LMAT or BLCO?

Which has more risk and volatility, LMAT or BLCO?

Which has stronger earnings & valuation, LMAT or BLCO?

Is LMAT or BLCO more profitable?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Do analysts rate STVN or LMAT?

Is STVN or LMAT more profitable?

Does the media prefer STVN or LMAT?

Which has more volatility and risk, STVN or LMAT?

Which has stronger earnings and valuation, STVN or LMAT?

Do institutionals & insiders hold more shares of STVN or LMAT?

Summary

How does LeMaitre Vascular compare to Liquidia?

Do insiders & institutionals have more ownership in LMAT or LQDA?

Which has more risk and volatility, LMAT or LQDA?

Is LMAT or LQDA more profitable?

Which has higher valuation and earnings, LMAT or LQDA?

Does the media favor LMAT or LQDA?

Do analysts prefer LMAT or LQDA?

Summary

How does LeMaitre Vascular compare to LivaNova?

Which has better valuation and earnings, LIVN or LMAT?

Is LIVN or LMAT more profitable?

Do insiders and institutionals believe in LIVN or LMAT?

Do analysts prefer LIVN or LMAT?

Does the media prefer LIVN or LMAT?

Which has more volatility and risk, LIVN or LMAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools